Suppr超能文献

汇聚结构阐明了种系抗体结合和泛拉沙病毒中和的特征。

Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.

机构信息

La Jolla Institute for Immunology, La Jolla, CA, USA; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.

University of Texas Medical Branch, Galveston National Laboratory, Galveston, TX, USA.

出版信息

Cell. 2019 Aug 8;178(4):1004-1015.e14. doi: 10.1016/j.cell.2019.07.020.

Abstract

Lassa virus (LASV) causes hemorrhagic fever and is endemic in West Africa. Protective antibody responses primarily target the LASV surface glycoprotein (GPC), and GPC-B competition group antibodies often show potent neutralizing activity in humans. However, which features confer potent and broadly neutralizing antibody responses is unclear. Here, we compared three crystal structures of LASV GPC complexed with GPC-B antibodies of varying neutralization potency. Each GPC-B antibody recognized an overlapping epitope involved in binding of two adjacent GPC monomers and preserved the prefusion trimeric conformation. Differences among GPC-antibody interactions highlighted specific residues that enhance neutralization. Using structure-guided amino acid substitutions, we increased the neutralization potency and breadth of these antibodies to include all major LASV lineages. The ability to define antibody residues that allow potent and broad neutralizing activity, together with findings from analyses of inferred germline precursors, is critical to develop potent therapeutics and for vaccine design and assessment.

摘要

拉沙病毒(LASV)会引起出血热,并且在西非流行。保护性抗体反应主要针对 LASV 表面糖蛋白(GPC),并且 GPC-B 竞争组抗体在人类中通常表现出有效的中和活性。然而,哪种特征赋予了强大且广泛的中和抗体反应尚不清楚。在这里,我们比较了三种 LASV GPC 与不同中和效力的 GPC-B 抗体的晶体结构。每个 GPC-B 抗体都识别一个重叠的表位,该表位涉及与两个相邻 GPC 单体的结合,并保持了预融合三聚体构象。GPC-抗体相互作用之间的差异突出了增强中和作用的特定残基。通过结构指导的氨基酸取代,我们提高了这些抗体的中和效力和广度,以包括所有主要的 LASV 谱系。能够定义允许强大且广泛的中和活性的抗体残基,以及对推断的种系前体的分析结果,对于开发有效的治疗方法以及疫苗设计和评估至关重要。

相似文献

1
4
Structural basis for antibody-mediated neutralization of Lassa virus.
Science. 2017 Jun 2;356(6341):923-928. doi: 10.1126/science.aam7260.
5
Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies.
Cell Rep. 2023 May 30;42(5):112524. doi: 10.1016/j.celrep.2023.112524. Epub 2023 May 18.
8
Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies.
Cell Rep. 2022 May 24;39(8):110841. doi: 10.1016/j.celrep.2022.110841.
9
Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex.
Immunity. 2024 Sep 10;57(9):2061-2076.e11. doi: 10.1016/j.immuni.2024.06.013. Epub 2024 Jul 15.

引用本文的文献

1
Metal-induced conformational changes in the Sabiá virus spike complex.
Nat Microbiol. 2025 Aug 1. doi: 10.1038/s41564-025-02075-8.
2
Infusion of neutralization into Lassa vaccine design.
Trends Immunol. 2025 Jul;46(7):512-524. doi: 10.1016/j.it.2025.05.006. Epub 2025 Jun 24.
4
Public antibodies: convergent signatures in human humoral immunity against pathogens.
mBio. 2025 May 14;16(5):e0224724. doi: 10.1128/mbio.02247-24. Epub 2025 Apr 16.
5
Mapping the antibody response to Lassa virus vaccination of non-human primates.
EBioMedicine. 2025 Apr;114:105673. doi: 10.1016/j.ebiom.2025.105673. Epub 2025 Mar 31.
6
Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV.
NPJ Vaccines. 2025 Feb 22;10(1):37. doi: 10.1038/s41541-025-01090-4.
7
Architectural organization and fusion protein structure of lymphocytic choriomeningitis virus.
J Virol. 2024 Oct 22;98(10):e0064024. doi: 10.1128/jvi.00640-24. Epub 2024 Sep 27.
9
Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex.
Immunity. 2024 Sep 10;57(9):2061-2076.e11. doi: 10.1016/j.immuni.2024.06.013. Epub 2024 Jul 15.
10
Strategies of rational and structure-driven vaccine design for Arenaviruses.
Infect Genet Evol. 2024 Sep;123:105626. doi: 10.1016/j.meegid.2024.105626. Epub 2024 Jun 20.

本文引用的文献

1
Broadly Neutralizing Antibodies against HIV: Back to Blood.
Trends Mol Med. 2019 Mar;25(3):228-240. doi: 10.1016/j.molmed.2019.01.007. Epub 2019 Feb 18.
3
Structure of the Lassa virus glycan shield provides a model for immunological resistance.
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7320-7325. doi: 10.1073/pnas.1803990115. Epub 2018 Jun 25.
5
Nigeria hit by unprecedented Lassa fever outbreak.
Science. 2018 Mar 16;359(6381):1201-1202. doi: 10.1126/science.359.6381.1201.
6
New Lineage of Lassa Virus, Togo, 2016.
Emerg Infect Dis. 2018 Mar;24(3):599-602. doi: 10.3201/eid2403.171905.
7
Emergence of Lassa Fever Disease in Northern Togo: Report of Two Cases in Oti District in 2016.
Case Rep Infect Dis. 2017;2017:8242313. doi: 10.1155/2017/8242313. Epub 2017 Dec 17.
8
Mortality Among Confirmed Lassa Fever Cases During the 2015-2016 Outbreak in Nigeria.
Am J Public Health. 2018 Feb;108(2):262-264. doi: 10.2105/AJPH.2017.304186. Epub 2017 Dec 21.
9
Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.
Nat Med. 2017 Oct;23(10):1146-1149. doi: 10.1038/nm.4396. Epub 2017 Sep 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验